Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:SYK
CUSIP86366710
Phone269-389-2600
Debt
Debt-to-Equity Ratio0.64
Current Ratio1.64
Quick Ratio1.08
Price-To-Earnings
Trailing P/E Ratio26.50
Forward P/E Ratio23.79
P/E Growth2.41
Sales & Book Value
Annual Sales$12.44 billion
Price / Sales5.17
Cash Flow$8.4231 per share
Price / Cash20.42
Book Value$26.67 per share
Price / Book6.45
Profitability
EPS (Most Recent Fiscal Year)$6.49
Net Income$1.02 billion
Net Margins8.00%
Return on Equity25.65%
Return on Assets11.68%
Miscellaneous
Employees33,000
Outstanding Shares373,710,000
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker declared a quarterly dividend on Thursday, May 3rd. Stockholders of record on Friday, June 29th will be paid a dividend of $0.47 per share on Tuesday, July 31st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date of this dividend is Thursday, June 28th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) issued its quarterly earnings data on Thursday, April, 26th. The medical technology company reported $1.68 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.08. The medical technology company had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.20 billion. Stryker had a net margin of 8.00% and a return on equity of 25.65%. Stryker's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.48 EPS. View Stryker's Earnings History.
When is Stryker's next earnings date?
What guidance has Stryker issued on next quarter's earnings?
Stryker updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $7.18-$7.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.13.
What price target have analysts set for SYK?
22 brokers have issued 12-month price targets for Stryker's stock. Their forecasts range from $132.00 to $187.00. On average, they expect Stryker's share price to reach $170.6842 in the next twelve months. View Analyst Ratings for Stryker.
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. According to Zacks Investment Research, "Stryker outperformed the industry in a year’s time. Continued demand for the Mako Total Knee Platform and a diversified product portfolio have consistently driven the company’s growth. The company’s high domestic and international growth in revenues also buoy optimism. A strong guidance for the second quarter and full year holds promise. Moreover, surging operating margins reflect the company’s bullish prospects. Stryker’s acquisition-driven strategy is expected to boost growth by expanding existing product offerings across all business segments, while an enhanced international presence should bolster its global hold. However, supply issues in the Puerto Rico facility and a declining gross margin raise concern. Furthermore, the recall of the Oral Care lineup is a major drawback. The company is currently being plagued by foreign currency volatility and reduced demand for healthcare products." (6/20/2018)
- 2. Cantor Fitzgerald analysts commented, ". This morning (6/11), Journal reported that SYK made a takeover approach of Boston Scientific (Not Covered). Trading on both stocks was halted for a period of time during the day. BSX released an 8-K saying that it was aware of the story, but in accordance with company practice, it does not comment on market rumors or speculation. SYK made similar comment when we reached out directly to them. We view SYK’s potential interest positively, although as somewhat unexpected." (6/13/2018)
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN) and Haemonetics (HAE).
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman ,CEO & Pres (Age 53)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 56)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 56)
- Mr. Timothy J. Scannell, Group Pres of MedSurg & Neurotechnology (Age 53)
- Mr. David K. Floyd, Group Pres of Orthopaedics (Age 57)
Has Stryker been receiving favorable news coverage?
Headlines about SYK stock have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stryker earned a news impact score of 0.16 on Accern's scale. They also gave press coverage about the medical technology company an impact score of 46.75 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Stryker's major shareholders?
Stryker's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.40%), Greenleaf Trust (6.24%), Massachusetts Financial Services Co. MA (2.29%), Franklin Resources Inc. (1.73%), Northern Trust Corp (1.02%) and OppenheimerFunds Inc. (0.53%). Company insiders that own Stryker stock include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Roch Doliveux, Ronda E Stryker, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which institutional investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., Greenleaf Trust, Massachusetts Financial Services Co. MA, Swiss National Bank, Yacktman Asset Management LP, Envestnet Asset Management Inc. and Northern Trust Corp. Company insiders that have sold Stryker company stock in the last year include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, William E Berry Jr and Yin C Becker. View Insider Buying and Selling for Stryker.
Which institutional investors are buying Stryker stock?
SYK stock was bought by a variety of institutional investors in the last quarter, including AustralianSuper Pty Ltd, BlackRock Inc., WCM Investment Management CA, Carmignac Gestion, Summit Trail Advisors LLC, Royal Bank of Canada, Darrell & King LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $172.00.
How big of a company is Stryker?
Stryker has a market capitalization of $63.36 billion and generates $12.44 billion in revenue each year. The medical technology company earns $1.02 billion in net income (profit) each year or $6.49 on an earnings per share basis. Stryker employs 33,000 workers across the globe.
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
